677302-44-2

Basic information

• Product Name: 1-(Phenylsulfonyl)-4-azaindole
• Synonyms: 1-(Phenylsulfonyl)-4-azaindole
• CAS NO: 677302-44-2
• Molecular Formula: C₁₃H₁₀N₂O₂S
• Molecular Weight: 258.2957
• Mol File: 677302-44-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 465.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.34±0.1 g/cm3(Predicted)
• PKA: 4.32±0.30(Predicted)
• CAS DataBase Reference: 1-(Phenylsulfonyl)-4-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Phenylsulfonyl)-4-azaindole(677302-44-2)
• EPA Substance Registry System: 1-(Phenylsulfonyl)-4-azaindole(677302-44-2)

Safety Data

• Hazardous Substances Data: 677302-44-2(Hazardous Substances Data)

Usage

Class

Sulfonylindole compounds

Usage

Organic synthesis and pharmaceutical research

Applications

Drug discovery and development

Structure

Unique, making it a valuable building block for potential drug candidates

Biological activities

Exhibits various biological activities

Potential use

Treatment of diseases such as cancer and inflammation

Further research

May lead to the development of new and effective pharmaceuticals

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 98-09-9 benzenesulfonyl chloride 

Downstream Products

• 17288-52-7 1H-pyrrolo[3,2-b]pyridine-2-carbaldehyde 
• 677302-46-4 1-(benzenesulfonyl)-4-oxido-pyrrolo[3,2-b]pyridin-4-ium 

Relevant articles and documents

Peptidylarginine deiminase inhibitor and application thereof

The invention belongs to the technical field of medicine, and particularly relates to a peptidylarginine deiminase PAD4 inhibitor compound shown in a formula (I) or pharmaceutically acceptable salts,stereoisomers and tautomers thereof, as well as pharmaceutical compositions, pharmaceutical preparations and application thereof. X, Y, R1, R2, R3, R4, R5, R7, R8, R9, ring B and m are as defined in the specification. The compound has inhibitory effect on peptidylarginine deiminase PAD4, and can be used for treating various diseases, such as rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, multiple sclerosis, cystic fibrosis, cancer, cutaneous lupus erythematosus, asthma and psoriasis.

Discovery of 4-azaindoles as novel inhibitors of c-Met kinase

A series of 4-azaindole inhibitors of c-Met kinase is described. The postulated binding mode was confirmed by an X-ray crystal structure and series optimisation was performed on the basis of this structure. Future directions for series development are dis